^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    12h
    Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma (clinicaltrials.gov)
    P1, N=9, Enrolling by invitation, Beijing Neurosurgical Institute
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • IDH wild-type
    12h
    METLUNG: Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (clinicaltrials.gov)
    P3, N=312, Recruiting, Instituto Nacional de Cancerologia de Mexico | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    STK11 (Serine/threonine kinase 11) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
    |
    EGFR mutation
    |
    metformin
    20h
    BG-60366-101: A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, BeOne Medicines | N=93 --> 33 | Trial completion date: Apr 2028 --> May 2026 | Trial primary completion date: Apr 2028 --> May 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR mutation
    21h
    Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. (clinicaltrials.gov)
    P=N/A, N=74, Recruiting, Instituto Nacional de Cancerologia de Mexico | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    nitroglycerin
    23h
    A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=218, Completed, Sandoz | Suspended --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin
    1d
    Targeted therapy in the treatment of lung cancer in Iceland 2010-2023. (PubMed, Acta Oncol)
    The use of molecular testing has increased significantly in the last 20 years, and the -adaptation of new targeted therapies has been rapid.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • BRAF mutation
    1d
    Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study). (PubMed, JTO Clin Res Rep)
    Adjuvant atezolizumab with cisplatin and vinorelbine did not significantly improve DFS compared with patients with resected EGFR-mutated NSCLC. These results highlight the limited benefit of immune checkpoint inhibitors in this population and the need for predictive biomarkers to guide immunotherapy strategies for improving cure rates.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tecentriq (atezolizumab) • vinorelbine tartrate
    1d
    Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR-Mutant NSCLC. (PubMed, Cancer Med)
    Finally, we address emerging biomarkers and innovative detection methods, offering recommendations for enhancing the application of liquid biopsy in clinical settings. Our review aims to underscore the significance of liquid biopsy in improving the detection and management of BM.
    Review • Journal • Liquid biopsy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    1d
    LncRNA HCP5 remodels G6PD dual post-translational modification to mediate metabolic adaptations driving osimertinib resistance in lung adenocarcinoma. (PubMed, J Adv Res)
    HCP5 drives osimertinib resistance through dual post-translational regulation of G6PD-blocking ubiquitination and promoting deacetylation-leading to metabolic adaptation. Targeting the HCP5-G6PD axis is a potential treatment strategy to overcome osimertinib resistance in LUAD.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    1d
    Structure-guided discovery of a potent 2-aryl-4-aminoquinazoline-based inhibitor overcoming osimertinib resistance driven by EGFR C797S mutation in NSCLC. (PubMed, Eur J Med Chem)
    In a PC-9Del19/T790M/C797S xenograft model, 6g achieved significant dose-dependent tumor growth inhibition (TGI: 47.3% at 5 mg/kg; 64.2% at 10 mg/kg), markedly surpassing Osimertinib (TGI: 16.07% at 10 mg/kg), with no observed significant toxicity. These results establish 6g as a promising fourth-generation EGFR-TKI candidate with potent activity, favorable pharmacokinetics, and a high safety profile, offering a potential therapeutic strategy against Osimertinib resistance driven by the C797S mutation.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    Tagrisso (osimertinib)
    1d
    ETV6-NTRK3 as a resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: favorable response after combination of osimertinib and entrectinib: a case report and literature review. (PubMed, Front Pharmacol)
    Combination therapy with osimertinib and entrectinib induced regression of pulmonary lesions, but the patient ultimately discontinued all targeted agents due to the development of severe hepatorenal failure and Escherichia coli-associated sepsis. This case highlights the need for additional research into the safety profile of EGFR-TKI/NTRK inhibitor combination regimens in resistant NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • HER-2 amplification • EGFR exon 19 deletion • MET amplification • MET mutation
    |
    Tagrisso (osimertinib) • Rozlytrek (entrectinib)
    1d
    LAURA: Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study (clinicaltrials.gov)
    P2, N=60, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib)